Congress quietly expands R&D tax breaks for tech and biotech giants
S. 1639 — American Innovation and Jobs Act · Filed by Todd Young (R-IN) · 35 cosponsors · Introduced May 7, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill restores and expands tax breaks for companies that spend money on research and development. It allows businesses to immediately deduct R&D costs from their taxes (rather than spreading the deduction over years), increases the refundable research credit cap from $250,000 to $750,000 by 2035 for small and startup companies, and makes it easier for new businesses to claim these credits. The primary beneficiaries are tech companies, biotech firms, logistics providers, and other R&D-intensive businesses.
Why we flagged it
The bill's core function is to reduce tax liability for R&D-intensive corporations and startups through immediate expensing, expanded refundable credits, and relaxed eligibility rules. It is fundamentally a tax expenditure benefiting private business, not a public investment or regulatory reform.
What the text implies
- The bill front-loads tax deductions, allowing companies to claim R&D costs immediately rather than over time, which accelerates cash flow benefits to profitable firms while reducing near-term federal revenue.
- Expanding the refundable research credit cap to $750,000 by 2035 primarily benefits venture-backed startups and growth-stage companies that can afford to invest heavily in R&D; early-stage or capital-constrained firms may not reach the threshold.
The full analysis lists 5 implications of this text.
Who stands to gain
technology companies; biotechnology firms; logistics and delivery platforms